United Therapeutics Corporation (UTHR) Stock Analysis
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. At $545.40, A.R:R 1.2:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: Tyvaso DPI and Nebulized Tyvaso (59.0%); Concentration risk — Supplier: MannKind.
United Therapeutics (a public benefit corporation) markets five FDA-approved therapies for pulmonary arterial hypertension and Unituxin for neuroblastoma, with Tyvaso DPI and Nebulized Tyvaso combined representing 59% of 2025 revenues. Revenue comes primarily from sales to... Read more
Sell if holding. At $545.40, A.R:R 1.2:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: Tyvaso DPI and Nebulized Tyvaso (59.0%); Concentration risk — Supplier: MannKind. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.7/10, moderate confidence.
Passes 6/8 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 47d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: moderate.
Recent developments
updated 2026-06-12Recent Developments — United Therapeutics Corporation
Latest news
- NEWS United Therapeutics chairperson & CEO Martine Rothblatt sells $5.4m in stock - Investing.com — Investing.com negative
- NEWS UTHR stock rises 12.5% on promising data from TETON-1 Tyvaso study - MSN — MSN positive
- NEWS United Therapeutics (UTHR) Board Restructures Ahead of 2026 Meeting - GuruFocus — GuruFocus neutral
- NEWS Analysts’ Opinions Are Mixed on These Healthcare Stocks: United Therapeutics (UTHR), Insmed (INSM) and MannKind (MNKD) - — The Globe and Mail neutral
- NEWS United Therapeutics (NASDAQ:UTHR) Reports Sales Below Analyst Estimates In Q1 CY2026 Earnings - StockStory — StockStory negative
Generated 2026-06-15T18:11:47Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductTyvaso DPI and Nebulized Tyvaso59%10-K Item 1: 'combined Tyvaso DPI and Nebulized Tyvaso net product sales, representing 59 percent...of our total revenues for the years ended December 31, 2025'
- HIGHSupplierMannKind10-K Item 1A: 'We rely entirely on MannKind to manufacture Tyvaso DPI finished drug product and inhalers for us, with no plans to develop an alternate or backup supply arrangement'
- HIGHCustomerAccredo and CVS Specialty10-K Item 1A: 'we derive substantially all our treprostinil-based revenues from sales to two distributors, Accredo and CVS Specialty'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Revenue shrinking — -1.6% YoY. Growth thesis broken unless recovery story develops.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $545.40, A.R:R 1.2:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: Tyvaso DPI and Nebulized Tyvaso (59.0%); Concentration risk — Supplier: MannKind. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $520.08. Score 4.7/10, moderate confidence.
Take-profit target: $578.75 (+6.1% upside). Prior stop was $520.08. Stop-loss: $520.08.
Concentration risk — Product: Tyvaso DPI and Nebulized Tyvaso (59.0%); Concentration risk — Supplier: MannKind; Thin upside margin: 6.1%.
United Therapeutics Corporation trades at a P/E of 20.2 (forward 17.2). TrendMatrix value score: 5.6/10. Verdict: Sell.
22 analysts cover UTHR with a consensus score of 4.1/5. Average price target: $665.
What does United Therapeutics Corporation do?United Therapeutics (a public benefit corporation) markets five FDA-approved therapies for pulmonary arterial...
United Therapeutics (a public benefit corporation) markets five FDA-approved therapies for pulmonary arterial hypertension and Unituxin for neuroblastoma, with Tyvaso DPI and Nebulized Tyvaso combined representing 59% of 2025 revenues. Revenue comes primarily from sales to specialty distributors Accredo and CVS Specialty; MannKind is the sole Tyvaso DPI manufacturer with no backup arrangement.